Загрузка...
Engineering and In Vitro Selection of a Novel AAV3B Variant with High Hepatocyte Tropism and Reduced Seroreactivity
Limitations to successful gene therapy with adeno-associated virus (AAV) can comprise pre-existing neutralizing antibodies to the vector capsid that can block cellular entry, or inefficient transduction of target cells that can lead to sub-optimal expression of the therapeutic transgene. Recombinant...
Сохранить в:
| Опубликовано в: : | Mol Ther Methods Clin Dev |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Gene & Cell Therapy
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7591349/ https://ncbi.nlm.nih.gov/pubmed/33145371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omtm.2020.09.019 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|